Dr. Yu on Moderate Hypofractionation in Prostate Cancer

James B. Yu, MD, associate professor, therapeutic oncology, director, Prostate and Genitourinary Cancer Radiotherapy Program, Yale Cancer Center, discusses moderate hypofractionation replacing the current standard of care for patients with prostate cancer.

Moderate hypofractionation could potentially be adopted, replacing standard fractionation, if there are a couple more years of data.

Many academics have the opinion that moderate hypofractionation is the new standard therapy but additionally, many will also prefer to wait for more data to accrue, discusses Yu.